| Phase 4 |
| NCT05787509 |
Prolonged Progesterone to Prevent Preterm Birth From IVF - ET |
Preterm Birth |
Recruiting |
2026-06-11 |
| NCT06641544 |
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line… |
Metastatic Breast Cancer |
Recruiting |
2024-10-15 |
| NCT05682131 |
South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol |
Arsenic Trioxide |
Recruiting |
2023-01-12 |
| NCT07801183 |
Efficacy and Safety of Anrikefon Injection for Multimodal Postoperative Analgesia in… |
Postoperative Acute Pain |
Not Yet Recruiting |
2026-09-03 |
| NCT06487143 |
Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP |
Central Precocious Puberty |
Not Yet Recruiting |
2024-07-05 |
| NCT05910125 |
Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke |
Ischemic Stroke |
Not Yet Recruiting |
2023-06-18 |
| Phase 3 |
| NCT07137832 |
OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion |
Acute Ischemic Stroke |
Recruiting |
2026-08-24 |
| NCT07606807 |
rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window |
Acute Ischemic Stroke |
Recruiting |
2026-06-15 |
| NCT07400523 |
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual… |
Breast Cancer |
Recruiting |
2026-04-28 |
| NCT06889688 |
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in… |
Breast Cancer Stage IV |
Recruiting |
2026-04-23 |
| NCT06966245 |
External Mastalgia-oil Versus Placebo in Premenopausal Women With Severe Mastalgia |
Mastalgia |
Recruiting |
2026-02-02 |
| NCT07092709 |
Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users |
Acute Ischemic Stroke |
Recruiting |
2025-12-16 |
| NCT06172205 |
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and… |
BCLC Stage C Hepatocellular Carcinoma |
Recruiting |
2025-12-03 |
| NCT05760612 |
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth… |
Early-stage Breast Cancer |
Recruiting |
2025-09-25 |
| NCT06255392 |
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in… |
Fludzoparib" and Anti-angiogenic |
Recruiting |
2025-08-15 |
| NCT07066280 |
Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer |
Skin Microbiome |
Recruiting |
2025-07-15 |
| NCT05582265 |
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in… |
Head and Neck Squamous Cell Carcinomas |
Recruiting |
2024-05-17 |
| NCT06313463 |
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After… |
Breast Neoplasms |
Recruiting |
2024-03-15 |
| NCT06278870 |
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced… |
HER2-positive Metastatic Breast Cancer |
Recruiting |
2024-02-26 |
| NCT05159193 |
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential… |
Breast Cancer |
Recruiting |
2024-02-02 |
| NCT05980715 |
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC… |
HNSCC |
Recruiting |
2023-08-08 |
| NCT05904964 |
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer… |
HR Positive/HER2 Low Expression Metastatic Breast Cancer |
Recruiting |
2023-06-22 |
| NCT04646759 |
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer |
Breast Cancer |
Recruiting |
2020-11-30 |
| NCT06144944 |
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer |
Breast Cancer Invasive |
Active, Not Recruiting |
2026-08-18 |
| NCT07761325 |
Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for… |
Breast Cancer |
Not Yet Recruiting |
2026-08-12 |